Lupin Pharmaceuticals’ smooth-run in Japan; all eyes on biosimilars growth

which would come from biosimilars and it expects nearly 50 per cent of its Japan sales to come from the speciality business. Lupin’s Japan story assumes significance as it held on to the highly regulated market, when most of its Indian peers quit.
( read original story …)


Related Post

Japan May Manufacturing Growth Slows to Six-Month ...
views 259
TOKYO (Reuters) - Japanese manufacturing activity ...
Tokyo: Matsuzaka joins cast of Chen Kaige’s ...
views 261
The casting was announced today at Tokyo Internati...
Japan’s Aso ‘Feels Sorry’ for Mnuchin Amid Outrage...
views 96
U.S. Treasury Secretary Steven Mnuchin faced so mu...
Japan’s silver-tongued Lotharios sell dreams to lo...
views 264
TOKYO, Japan – Cigarette smoke hangs thick in the ...
Bank of Japan Governor says Fed rate hikes good fo...
views 52
Bank of Japan Governor Haruhiko Kuroda said on Sat...
Japan Jewellery Fair 2018 Encourages Buoyant Retai...
views 70
TOKYO, Aug. 28, 2018 /PRNewswire/ -- Japan's most ...
In Tokyo, Pence praises U.S.-Japan alliance as ‘mo...
views 35
The “U.S.-Japan alliance is the cornerstone of pea...
China online insurer ZhongAn prices Hong Kong IPO ...
views 176
It cited people close to the deal. The insurer dec...
Nagoya aquarium discovers a grouper that likes to ...
views 230
NAGOYA – A longtooth grouper in a Nagoya aqu...
Light earthquake 4.8 mag, 25 km NE of Iwaki, Japan
views 76
A light earthquake magnitude 4.8 (ml/mb) has occur...